trazodone has been researched along with Clerambault Syndrome in 6 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"Trazodone was associated with the occurrence of life-threatening premature ventricular contractions and angina in a 45-year-old white man who had no prior cardiovascular disease." | 5.27 | A case of trazodone-induced ventricular tachycardia. ( Aronson, MD; Hafez, H, 1986) |
"Seven patients with organic mental disorders and physically aggressive behavior were treated with trazodone." | 2.66 | Effects of trazodone on aggressive behavior in seven patients with organic mental disorders. ( Pinner, E; Rich, CL, 1988) |
"Trazodone was associated with the occurrence of life-threatening premature ventricular contractions and angina in a 45-year-old white man who had no prior cardiovascular disease." | 1.27 | A case of trazodone-induced ventricular tachycardia. ( Aronson, MD; Hafez, H, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (83.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lehmann, HE | 1 |
Ban, TA | 1 |
Schwartz, GV | 1 |
Silver, JM | 1 |
Hales, RE | 1 |
Yudofsky, SC | 1 |
Aronson, MD | 1 |
Hafez, H | 1 |
Simpson, DM | 1 |
Foster, D | 1 |
Pinner, E | 1 |
Rich, CL | 1 |
Ravizza, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury[NCT00704379] | Phase 2/Phase 3 | 94 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Iowa Gambling Task (IGT) evaluates decision making ability. During IGT subjects have to choose between decks of cards which yield high immediate gain but larger future loss (i.e., long term loss), and decks which yield lower immediate gain but a smaller future loss (i.e., a long term gain). The task consists of four decks of cards: A, B, C, and D. The goal in the task is to maximize profit. Subjects are required to make a series of card selections. The decks A and B are long term loss decks and the decks C and D are long term gain decks. The IGT Score reported is the combination of the raw score for each deck combined in the following way: (C+D) - (A+B). The range for this score is: -100 to 100. Higher values of this score indicate better decision making ability. (NCT00704379)
Timeframe: 6 months after TBI
Intervention | units on a scale (Mean) |
---|---|
Placebo | 16.67 |
Sertraline | -0.77 |
This outcome measures memory function and is a composite of five standardized scores: Brief Visuospatial Memory Test - Revised, Delayed Recall and California Verbal Learning Test, Short Delay Free Recall Number Correct and Discriminability, and Long Delay Free Recall Number Correct and Discriminability. Standardized scores (i.e., z-scores) for each test of this composite were obtained by subtracting the mean raw score of all participants to the raw score of each participant and dividing the result by the standard deviation of the raw scores of all participants. The composite score was obtained by averaging the z-scores of the four memory tests mentioned previously. Range: -3 to 3. Higher scores represent better memory function. (NCT00704379)
Timeframe: 6 months following traumatic brain injury
Intervention | z-scores (Mean) |
---|---|
Placebo | -0.08 |
Sertraline | 0.07 |
"FA is a measured obtained from Diffusion Tensor Imaging, an image modality of Magnetic Resonance Imaging (MRI). FA is a unitless index. Range: 0 to 1. FA describes the degree of anisotropy of a diffusion process. A value of zero means that diffusion is unrestricted or equally restricted in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions. In the context of this study, FA measures the integrity of the cingulate gyrus white matter. Higher FA values reflect higher integrity of the cingulate gyrus white matter tract. Average FA values for the right and left cingulate gyri were summed.~One aim of this project was to identify predictors of the occurrence of mood disturbances during the first 6 months following TBI. The hypothesis for this aim was that patients who develop a mood or anxiety disorder six months after TBI present at baseline with lower FA of the cingulate gyrus than those who do not." (NCT00704379)
Timeframe: Baseline
Intervention | unitless index (Mean) |
---|---|
Patients Who Developped a Mood or Anxiety Disorder | 0.91 |
Patients Who Did Not Developped a Mood or Anxiety Disorder | 0.94 |
The Social Functioning Examination (SFE) is a semi-structured interview that measures social functioning in areas such as interpersonal relationships, work adjustment, use of community resources and satisfaction with living environment. Range: 0 to 1. Higher scores denote lower levels of social functioning. (NCT00704379)
Timeframe: 6 months after TBI
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.04 |
Sertraline | 0.04 |
"Following the DSM-IV (now updated by the DSM-5), depressive disorders associated with TBI are categorized as Mood Disorder Due to Another Medical Condition with subtypes: 1) With major depressive-like episode (if the full criteria for a major depressive episode [MDE] are met) or 2) With depressive features (prominent depressed mood but full criteria for a MDE are not met); and 3) with mixed features (e.g. significant irritability, pressured speech and formal thought disorder).~On the other hand, bipolar and related disorders due to TBI are subdivided in: 1) with manic or hypomanic like episode; 2) with manic features; and 3) with mixed features.~A similar conceptual framework has been used to define Anxiety Disorder due to another Medical Condition, in this case, TBI. According to DSM-IV/DSM-5, such diagnosis can be made when, besides an evident pathophysiological relationship with TBI, panic attacks or generalized anxiety are the prominent features of the clinical presentation." (NCT00704379)
Timeframe: 6 months after TBI
Intervention | weeks (Mean) |
---|---|
Placebo | 21.4264 |
Sertraline | 15.7833 |
The Community Integration Questionnaire (CIQ) is intended as a brief, reliable measure of an individual's level of integration into the home and community following traumatic brain injury. Total CIQ scores were used as the outcome measure. Range: 0 to 25. Higher scores indicate higher levels of integration into the home and community following TBI. (NCT00704379)
Timeframe: 6 months after TBI
Intervention | units on a scale (Mean) |
---|---|
Placebo | 16.77 |
Sertraline | 17.67 |
1 review available for trazodone and Clerambault Syndrome
Article | Year |
---|---|
Psychopharmacology of depression in neurologic disorders.
Topics: Amitriptyline; Antidepressive Agents; Depressive Disorder; Electroconvulsive Therapy; Humans; Nervou | 1990 |
2 trials available for trazodone and Clerambault Syndrome
Article | Year |
---|---|
Psychotherapeutic profile of a new psychoactive drug trazodone (AF-1161).
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Female; Humans; Male; Mental Disorders; Middle Ag | 1975 |
Effects of trazodone on aggressive behavior in seven patients with organic mental disorders.
Topics: Aged; Aggression; Behavior Therapy; Clinical Trials as Topic; Humans; Male; Middle Aged; Neurocognit | 1988 |
3 other studies available for trazodone and Clerambault Syndrome
Article | Year |
---|---|
A case of trazodone-induced ventricular tachycardia.
Topics: Angina Pectoris; Cardiac Complexes, Premature; Depressive Disorder; Electrocardiography; Heart Ventr | 1986 |
Improvement in organically disturbed behavior with trazodone treatment.
Topics: Aged; Aggression; Alcohol Amnestic Disorder; Alzheimer Disease; Animals; Antipsychotic Agents; Human | 1986 |
Diagnostic and therapeutic problems in the psychopharmacological treatment of the elderly patient.
Topics: Aged; Aging; Depressive Disorder; Diagnosis, Differential; Humans; Kinetics; Mental Disorders; Neuro | 1986 |